HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J Am Dent Assoc, Vol 132, No 4, 451-456. © 2001 American Dental Association

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MOORE, P. A. Articles by HERSH, E. V. Search for Related Content PubMed PubMed Citation Articles by MOORE, P. A. Articles by HERSH, E. V. Related Collections Pharmacology

COVER STORY

The role of COX-2 inhibitors in dental practice

Background. In recent years, dental practitioners have relied on ibuprofen and other nonsteroidal anti-inflammatory drugs, or NSAIDs—such as naproxen, diflunisal and ketoprofen—to manage acute and chronic orofacial pain. Two NSAIDs that recently came on the market, celecoxib and rofecoxib, have been developed to limit the adverse effects seen after chronic use of NSAIDs.

Literature Reviewed. The authors have summarized all available publications describing the human pharmacokinetics, clinical pharmacology and known adverse effects of these new specific cyclo-oxygenase-2, or COX-2, inhibitors.

Conclusions. Although peripherally acting analgesics are remarkably effective, chronic administration of nonselective COX inhibitors has been associated with gastrointestinal ulceration and prolonged bleeding. The authors present the distinctive mechanism of action for these new COX-2 inhibitors, compare their relative anti-inflammatory and analgesic properties and describe their safety profile. They also summarize indications, contraindications and dosing recommendations.

Clinical Implications. Celecoxib and rofecoxib are valuable dental therapeutic agents for the management of inflammatory joint disorders and associated chronic orofacial pain. Additionally, rofecoxib, with its more rapid onset, may be useful in treating selected cases of acute postsurgical pain.

This article has been cited by other articles:

				T.C.B. Schutz, M.L. Andersen, and S. Tufik Effects of COX-2 Inhibitor in Temporomandibular Joint Acute Inflammation Journal of Dental Research, May 1, 2007; 86(5): 475 - 479. [Abstract] [Full Text] [PDF]

				M. A. Huber and G. T. Terezhalmy The use of COX-2 inhibitors for acute dental pain: A second look J Am Dent Assoc, April 1, 2006; 137(4): 480 - 487. [Abstract] [Full Text] [PDF]

				M. SPINK, S. BAHN, and R. GLICKMAN Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: Benefits and risks J Am Dent Assoc, October 1, 2005; 136(10): 1439 - 1448. [Abstract] [Full Text] [PDF]

				A. H. JESKE Selecting new drugs for pain control: Evidence-based decisions or clinical impressions? J Am Dent Assoc, August 1, 2002; 133(8): 1052 - 1056. [Abstract] [Full Text] [PDF]

				D. R. MEHLISCH The efficacy of combination analgesic therapy in relieving dental pain J Am Dent Assoc, July 1, 2002; 133(7): 861 - 871. [Abstract] [Full Text] [PDF]

				S. E. DANIELS, P. J. DESJARDINS, S. TALWALKER, D. P. RECKER, and K. M. VERBURG The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery J Am Dent Assoc, May 1, 2002; 133(5): 611 - 621. [Abstract] [Full Text] [PDF]